Lunit Partners with 10x Genomics to Enhance Oncology Biomarker Discovery — Lunit Inc.

Event summary

Lunit's AI-powered pathology platform, Lunit SCOPE IO, will be integrated into 10x Genomics' oncology biomarker discovery workflow.
The collaboration aims to combine spatial molecular data from 10x Genomics with Lunit's H&E pathology analysis.
Initial focus will be on clinical research studies for antibody-drug conjugates and immunotherapy response prediction.
Lunit SCOPE IO uses deep learning to analyze whole-slide H&E pathology images and characterize tissue features.
The collaboration was announced on September 10, 2026.

The big picture

This collaboration between Lunit and 10x Genomics highlights the growing trend of integrating AI-powered pathology analysis with spatial molecular data to advance oncology research. By combining their respective strengths, the partnership aims to provide a more complete view of tumors, potentially accelerating biomarker discovery and treatment strategies. The integration of Lunit's AI capabilities with 10x Genomics' spatial biology technologies positions them at the forefront of precision oncology, addressing the complex needs of cancer research and treatment.

What we're watching

Technology Integration: How effectively Lunit and 10x Genomics can combine their technologies to provide a more comprehensive view of tumor biology.
Market Impact: Whether this collaboration will accelerate the discovery of biomarkers that could inform treatment strategies and enable future diagnostic development.
Regulatory Pathways: The pace at which the combined technologies will transition from research use to potential diagnostic applications in oncology.